MedTrace Logo

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

NCT07310797 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-12-30

No results posted yet for this study

Summary

This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.

Conditions

  • Ureteral Calculi

Interventions

DRUG

Mirabegron

50 mg tablet orally once daily.

DRUG

Tamsulosin

0.4 mg tablet orally once daily.

Sponsors & Collaborators

  • Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    lead OTHER

Principal Investigators

  • Shu-Yu Wu, MD · Taichung Tzu Chi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2029-12-31
Completion
2030-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07310797 on ClinicalTrials.gov